<DOC>
	<DOCNO>NCT02906813</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability ( BA ) 300 milligram ( mg ) TAK-935 tablet compare 300 mg TAK-935 solution determine effect food BA TAK-935 300 mg tablet healthy adult participant .</brief_summary>
	<brief_title>A Study Determine Bioavailability Food Effect Single TAK-935 Dose Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-935 . The study look relative BA TAK-935 300 mg tablet compare TAK-935 300 mg oral solution ass effect food BA TAK-935 300 mg tablet healthy adult participant . The study enroll approximately 9 participant . Participants randomly assign ( chance , like flip coin ) one 3 treatment sequence : - TAK-935 ( 300 mg Tablets Fed + 300 mg Tablets Fasted + 300 mg Solution Fasted ) - TAK-935 ( 300 mg Tablets Fasted + 300 mg Solution Fasted + 300 mg Tablets Fed ) - TAK-935 ( 300 mg Solution Fasted + 300 mg Tablets Fed + 300 mg Tablets Fasted ) Administration dose separate washout period least 3 day . Participants ask take single dose TAK-935 tablet oral solution Day 1 Intervention Period . This single center trial conduct United States . The overall time participate study 45 day . Participants remain confined clinic 3 day intervention period contact telephone 30 day last dose TAK-935 follow-up assessment .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Weighs least 45 kilogram ( kg ) body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening Day 2 . 1 . Has receive TAK935 previous clinical study therapeutic agent . 2 . Has history psychiatric disorder diagnose utilizing Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM 5 ) criterion . 3 . Has lifetime history drug abuse ( define illicit drug use ) lifetime history alcohol abuse prior screen visit unwilling agree abstain alcohol drug throughout study . One unit equivalent halfpint beer single measure spirit 1 small glass wine . 4 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 5 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody Screening know history human immunodeficiency virus infection . 6 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior CheckIn Day 1 . Cotinine test positive Screening CheckIn ( Day 1 ) . 7 . Has poor peripheral venous access . 8 . Has donate lose 450 milliliter ( mL ) blood volume ( include plasmapheresis ) , transfusion blood product within 30 day prior Day 1 Period 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>